Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025Blood

Transplantation in combination with CAR T-cell therapy for refractory/relapsed aggressive B-cell lymphoma after failure of CD19 CAR-T cell therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

AZA. Zhang

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows improved outcomes with transplantation and CAR T-cell therapy in aggressive B-cell lymphoma, suggesting enhanced survival post-CD19 failure.

Key Points

  • CAR T-cell therapy combined with transplantation yielded a median overall survival of 14.56 months in aggressive B-cell lymphoma patients.
  • The combination resulted in a complete response rate of 83.3% and a progression-free survival median of 9.21 months.
  • In this cohort, neurotoxicity was reported in 4.2% of patients, with a significant incidence of grade 3 cytokine release syndrome.
  • Effectiveness of bridging therapy was highlighted, as it may significantly enhance patient survival before transplantation.

Cite This Study

A. Zhang (2025) studied this question.

synapsesocial.com/papers/69362f634fa91c937236de1bhttps://doi.org/10.1182/blood-2025-5484
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Long-term follow-up of patients with relapsed b-ALL after allo-HSCT treated with CD19 CAR-T cell from recipients and donors2025
  2. 2Sequential CD19/CD22 CAR-T cell therapy following ASCT shows improved efficacy versus CAR-t alone in relapsed/refractory large B-cell lymphoma2025
  3. 3CAR T-cell therapy versus autologous HSCT in patients with large B-cell lymphoma in complete remission: An analysis from the EBMT lymphoma working party2025 · 1 citations
  4. 4Safety and efficacy of CD19/CD22/CD20 multi-targeted CAR-T therapy in patients with refractory/relapsed B-cell non-Hodgkin lymphoma2025
  5. 5Propensity score-matched analysis supports the survival benefits of combination chimeric antigen receptor T-cell therapy with autologous transplantation in relapsed or refractory B-cell non-Hodgkin lymphoma: Insights from a real-world study in China2025